April Supplemental Approvals
This article was originally published in Pharmaceutical Approvals Monthly
You may also be interested in...
Juvenile Arthritis Data For Novartis' Ilaris Also Supports Role In Gouty Arthritis
Novartis' canakinumab shows promise in the first of two Phase III studies in systemic juvenile idiopathic arthritis, a severe and apparently distinct form of juvenile arthritis.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.